$19.44
6.11% yesterday
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US81750R1023
Symbol
MCRB

Seres Therapeutics Inc Stock price

$19.44
+7.05 56.90% 1M
+3.65 23.12% 6M
+2.82 16.97% YTD
+2.24 13.02% 1Y
-84.16 81.24% 3Y
-440.76 95.78% 5Y
-740.76 97.44% 10Y
-1,008.56 98.11% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+1.12 6.11%
ISIN
US81750R1023
Symbol
MCRB
Industry

Key metrics

Basic
Market capitalization
$170.2m
Enterprise Value
$124.8m
Net debt
positive
Cash
$45.4m
Shares outstanding
8.8m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.2
Financial Health
Equity Ratio
9.9%
Return on Equity
1.0%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | $-81.6m
EBIT
- | $-107.5m
Net Income
- | $-14.9m
Free Cash Flow
$-60.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | 27.5%
EBIT
- | 8.9%
Net Income
- | -10,764.3%
Free Cash Flow
67.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-6.9
Short interest
18.7%
Employees
103
Rev per Employee
$0.0
Show more

Is Seres Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Seres Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Seres Therapeutics Inc forecast:

7x Buy
70%
3x Hold
30%

Analyst Opinions

10 Analysts have issued a Seres Therapeutics Inc forecast:

Buy
70%
Hold
30%

Financial data from Seres Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 56 56
33% 33%
-
- Research and Development Expense 66 66
52% 52%
-
-120 -120
25% 25%
-
- Depreciation and Amortization 5.47 5.47
12% 12%
-
EBIT (Operating Income) EBIT -126 -126
22% 22%
-
Net Profit 0.14 0.14
100% 100%
-

In millions USD.

Don't miss a Thing! We will send you all news about Seres Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Seres Therapeutics Inc Stock News

Neutral
Seeking Alpha
16 days ago
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Carlo Tanzi - Corporate Participant Investor Relations - Corporate Participant Dennis M. Walling - Senior VP of Clinical Development & Head of Clinical Research Marella Thorell - Co-CEO, Co-President & CFO Matthew R.
Neutral
The Motley Fool
16 days ago
Seres (MCRB) Q2 Loss Narrows 34%
Neutral
GlobeNewsWire
17 days ago
Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure c...
More Seres Therapeutics Inc News

Company Profile

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Eric Shaff
Employees 103
Founded 2010
Website www.serestherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today